Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Sullivan, Sean D ^a   Alfonso Cristancho, Rafael ^a   Conner, Chris ^b   Hammer, Mette ^c   Blonde, Lawrence ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NOVO NORDISK INC   (United States)

^c NOVO NORDISK A S   (Denmark)

^d OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; SULFONYLUREA DERIVATIVE;

ADULT; AMPUTATION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE MODEL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ECONOMIC ASPECT; FOLLOW UP; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SIMULATION; SURVIVAL RATE; AGED; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 65349161010     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-12     Document Type: Article

References (48)

1. UKPDS Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998, 352:837-853. 10.1016/ S0140-6736(98)07019-6 9742976
2. Kahn SE Haffner SM Heise MA Herman WH Holman RR Jones NP Kravitz BG Lachin JM O'Neill MC Zinman B Viberti G ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006, 355:2427-2443. 10.1056/NEJMoa066224 17145742
3. Kasuga M Insulin resistance and pancreatic beta cell failure J Clin Invest 2006, 116:1756-1760. 1483164 16823472 10.1172/JCI29189
4. World Health Organization 2008 http://www.who.int/mediacentre/factsheets/ fs312/en/
5. CDC National Center for Chronic Disease Prevention and Health Promotion 2007 National Diabetes Fact Sheet http://www.cdc.gov/diabetes/pubs/ factsheet07.htm
6. American Diabetes Association Economic costs of diabetes in the US in 2007 Diabetes Care 2008, 31(Suppl 1):S1-S2. 10.2337/dc08-S001
7. Narayan KM Boyle JP Geiss LS Saaddine JB Thompson TJ Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050 Diabetes Care 2006, 29:2114-2116. 10.2337/dc06-1136 16936162
8. Caro JJ Ward AJ O'Brien JA Lifetime costs of complications resulting from type 2 diabetes in the US Diabetes Care 2002, 25:476-481. 10.2337/ diacare.25.3.476 11874933
9. Nichols GA Brown JB The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes Diabetes Care 2002, 25:482-486. 10.2337/diacare.25.3.482 11874934
10. O'Brien JA Patrick AR Caro J Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000 Clin Ther 2003, 25:1017-1038. 10.1016/S0149-2918(03)80122-4 12852716
11. Gilmer TP O'Connor PJ Rush WA Crain AL Whitebird RR Hanson AM Solberg LI Predictors of health care costs in adults with diabetes Diabetes Care 2005, 28:59-64. 10.2337/diacare.28.1.59 15616234
12. Kannel WB D'Agostino RB Wilson PW Belanger AJ Gagnon DR Diabetes, fibrinogen, and risk of cardiovascular disease: The Framingham experience Am Heart J 1990, 120:672-676. 10.1016/0002-8703(90)90026-T 2389702
13. Haffner SM Lehto S Rönnemaa T Pyörälä K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404 9673301
14. Stamler J Vaccaro O Neaton JD Wentworth D Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 1993, 16:434-444. 10.2337/ diacare.16.2.434 8432214
15. Malmberg K Yusuf S Gerstein HC Brown J Zhao F Hunt D Piegas L Calvin J Keltai M Budaj A Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry Circulation 2000, 102:1014-1019. 10961966
16. Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 2008, 358:580-591. 10.1056/NEJMoa0706245 18256393
17. Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008, 359:1577-1589. 10.1056/NEJMoa0806470 18784090
18. ADVANCE Collaborative Group Patel A MacMahon S Chalmers J Neal B Billot L Woodward M Marre M Cooper M Glasziou P Grobbee D Hamet P Harrap S Heller S Liu L Mancia G Mogensen CE Pan C Poulter N Rodgers A Williams B Bompoint S de Galan BE Joshi R Travert F Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008, 358:2560-2572. 10.1056/NEJMoa0802987 18539916
19. Clarke P Gray A Holman R Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) Med Decis Making 2002, 22:340-349. 10.1177/027298902400448902 12150599
20. Lloyd A Sawyer W Hopkinson P Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin Value Health 2001, 4:392-400. 10.1046/j.1524-4733.2001.45029.x 11705130
21. Huang ES Brown SE Ewigman BG Foley EC Meltzer DO Patient perceptions of quality of life with diabetes-related complications and treatments Diabetes Care 2007, 30:2478-2483. 2288662 17623824 10.2337/dc07-0499
22. Duckworth W Abraira C Moritz T Reda D Emanuele N Reaven PD Zieve FJ Marks J Davis SN Hayward R Warren SR Goldman S McCarren M Vitek ME Henderson WG Huang GD the VADT Investigators Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes N Engl J Med 2009, 360:129-139. 10.1056/NEJMoa0808431 19092145
23. Skyler JS Bergenstal R Bonow RO Buse J Deedwania P Gale EA Howard BV Kirkman MS Kosiborod M Reaven P Sherwin RS American Diabetes Association; American College of Cardiology Foundation; American Heart Association Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 2009, 32:187-192. 10.2337/dc08-9026 19092168
24. Vilsboll T Zdravkovic M Le-Thi T Krarup T Schmitz O Courreges J-P Verhoeven R Buganova I Madsbad S Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes Diabetes Care 2007, 30:1608-1610. 10.2337/dc06-2593 17372153
25. Marre M Shaw J Brandle M Wan Bebakar W Kamaruddin N Strand J Zdravkovic M Le-Thi TD Colagiuri S on behalf of the LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabet Med 2009, 26(3):268-278. 10.1111/ j.1464-5491.2009.02666.x 19317822
26. Nauck M Frid A Hermansen K Shah NS Tankova T Mitha IH During M Zdravkovic M Matthews D Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes Diabetes Care 2009, 32:84-90. 10.2337/dc08-1355 18931095
27. Garber A Henry R Ratner R Garcia-Hernadez PA Rodriguez-Pattzi H Olvera-Alvarez I Hale PM Zdravkovc M Bode B for the LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): Randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 2009, 373:473-481. 10.1016/ S0140-6736(08)61246-5 18819705
28. Zinman B Gerich J Buse J Lewin A Schwartz SL Raskin P Hale PM Zdravkovic M Blonde L Effect of the GLP-1 analog liraglutide on glycemic control and weight reduction in patients on metformin and rosiglitazone: A randomized double-blind placebo-controlled trial [abstract] Diabetologia 2008, 51(Suppl 1):S359.
29. Russell-Jones D Vaag A Schmitz O Sethi B Lalic NM Antic S Zdravkovic M Ravn GM Simo R Significantly better glycaemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: All as add-on to metformin + sulphonylurea in type 2 diabetes [abstract] Diabetologia 2008, 51(Suppl 1):S68.
30. Blonde L Rosenstock J Sesti G Schmidt WE Montanya E Brett J Zychma M Buse J Liraglutide: Superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes [abstract] Can J Diabetes 2008, 32(Suppl):A107.
31. Palmer AJ Roze S Valentine WJ Minshall ME Foos V Lurati FM Lammert M Spinas GA The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr Med Res Opin 2004, 20(Suppl 1):S5-S26. 10.1185/ 030079904X1980 15324513
32. Palmer AJ Roze S Valentine WJ Minshall ME Foos V Lurati FM Lammert M Spinas GA Validation of the CORE Diabetes Model against epidemiological and clinical studies Curr Med Res Opin 2004, 20(Suppl 1):S27-S40. 10.1185/030079904X2006 15324514
33. Brändle M Herman WH The CORE Diabetes Model Curr Med Res Opin 2004, 20(Suppl 1):S1-S3. 10.1185/030079904X1962 15324511
34. Palmer AJ Roze S Valentine WJ Minshall ME Hayes C Oglesby A Spinas GA Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: An analysis using the CORE Diabetes Model Curr Med Res Opin 2004, 20(Suppl 1):S53-S58. 10.1185/ 030079903125002611 15324516
35. Palmer AJ Roze S Valentine WJ Minshall ME Lammert M Oglesby A Hayes C Spinas GA What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model Curr Med Res Opin 2004, 20(Suppl 1):S59-S66. 10.1185/ 030079904X2024 15324517
36. Roze S Valentine WJ Zakrzewska KE Palmer AJ Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Diabet Med 2005, 22:1239-45. 10.1111/j.1464-5491.2005.01576.x 16108855
37. Watkins JB Minshall ME Sullivan SD Application of economic analyses in U.S. managed care formulary decisions: A private payer's experience J Manag Care Pharm 2006, 12:726-35. 17249905
38. Stratton IM Adler AI Neil HA Matthews DR Manley SE Cull CA Hadden D Turner RC Holman RR Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective, observational study BMJ 2000, 321:405-412. 27454 10938048 10.1136/ bmj.321.7258.405
39. Saaddine JB Cadwell B Gregg EW Engelgau MW Vinicor F Imperatore G Narayan V Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 1988-2002 Ann Intern Med 2006, 144:465-474. 16585660
40. Minshall ME Oglesby AK Wintle ME Valentine WJ Roze S Palmer AJ Estimating the long-term cost-effectiveness of exenatide in the United States: An adjunctive treatment for type 2 diabetes mellitus Value Health 2008, 11:22-33. 18237357
41. Tarn T Smith M Pharmacoeconomic Guidelines Around the World ISPOR Connections 2004, 1:5-15.
42. Fleming T Ed 2006 Drug Topics Red Book Thomson PDR, Montvale, NJ, USA 11 2006
43. Kantor J Margolis DJ Treatment options for diabetic neuropathic foot ulcers: A cost-effectiveness analysis Dermatologic Surgery 2001, 27:347-351. 10.1046/j.1524-4725.2001.00280.x 11298704
44. DRG Guidebook A Comprehensive Resource to the DRG Classification System St Anthony Press 17 2001.
45. Shearer A Scuffham P Gordois A Oglesby A Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S Diabetes Care 2003, 26:2305-2310. 10.2337/diacare.26.8.2305 12882853
46. American Diabetes Association Consensus Panel Guidelines for computer modeling of diabetes and its complications Diabetes Care 2004, 27:2262-2265. 10.2337/diacare.27.9.2262 15333499
47. Komajda M Curtis P Hanefeld M Beck-Nielsen H Pocock SJ Zambanini A Jones NP Gomis R Home PD for The RECORD Study Group Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/ sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study) Cardiovascular Diabetology 2008, 7:10. 2390513 18435852 10.1186/ 1475-2840-7-10
48. The Mt Hood 4 Modeling Group Computer Modeling of Diabetes and Its Complications Diabetes Care 2007, 30:1638-1646. 10.2337/dc07-9919 17526823